The Breath-Taking Lungs and Scleroderma
Toby Maher, MD, describes the increased prevalence of lung manifestations in scleroderma and the need for routine screening among these patients.
Interstitial Lung Disease
Rheumatoid Arthritis Associated With Increased Pulmonary Function Abnormalities on Spirometry
Researchers evaluated the association between rheumatoid arthritis and the type and severity of pulmonary patterns on spirometry.
RA-Associated Interstitial Lung Disease Mortality Rates and Trends Assessed
Although the overall rheumatoid arthritis-related mortality rates have been decreasing in recent years, rates of mortality among patients with rheumatoid arthritis-associated interstitial lung disease remain stable.
Tocilizumab Approved for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD.
Progressive ILD Trends in Systemic Sclerosis-Associated ILD
Close monitoring of patients with systemic sclerosis-associated interstitial lung disease and awareness of the variable course of progression is highly important in considering when to initiate treatment.
Usual Interstitial Pneumonia Pattern, But Not MTX Use, Linked to Acute Exacerbation of RA-ILD
Researchers evaluated the clinical characteristics and risk factors of acute exacerbations and mortality of rheumatoid arthritis-associated interstitial lung disease.
Nintedanib Clinically Beneficial in Progression of Systemic Sclerosis-Associated Interstitial Lung Disease
Study authors analyzed the effects of nintedanib on changes in forced vital capacity and other measures of progression in systemic sclerosis-associated interstitial lung disease.
Higher Neutrophil Count Linked to Mortality in Systemic Sclerosis-Related Interstitial Lung Disease
A higher neutrophil count predicted worse disease course and higher long-term mortality in patients with systemic sclerosis-related interstitial lung disease.
Adverse Event Profile of Nintedanib in SSc-ILD Consistent With its Safety, Tolerability Profile in Idiopathic Pulmonary Fibrosis
Researchers characterized the safety and tolerability of nintedanib and the dose adjustments for adverse events in patients with systemic sclerosis-associated interstitial lung disease.
Assessing Rates and Risk Factors for Interstitial Lung Disease in Patients With Rheumatoid Arthritis
Researchers investigated the incidence rates of interstitial lung disease in patients with rheumatoid arthritis receiving tofacitinib and identified potential risk factors.
- Loading...
Loading...
Next post in Rheumatoid Arthritis
Loading... 
Loading...